摘要 |
Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X<SUB>1 </SUB>is -S-, -O-, -N-N-. -NR<SUB>7</SUB>-, -CR<SUB>7</SUB>-CR<SUB>8</SUB>-, -CR<SUB>7</SUB>-N-, wherein R<SUB>7 </SUB>and R<SUB>8 </SUB>are independently hydrogen or C<SUB>1</SUB>-C<SUB>3 </SUB>alkyl; A is a carboxyl group -COOH, or a carboxyl bioisostere; rings Ar<SUP>2 </SUP>and Ar<SUP>3 </SUP>each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar<SUP>2 </SUP>and Ar<SUP>3</SUP>, or an optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q<SUB>1 </SUB>and Q<SUB>2 </SUB>represent substituents as defined in the description.
|